The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...
Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling. My life has changed ...
A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.
FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback